>
产品中心 >
Small_molecule >
Medchemexpress/Preladenant(Synonyms: SCH-420814)/HY-10889/10mM*1mL in DMSO
CustomerValidation
- •JNuclMed.2017May;58(5):762-767.
- •JMedChem.2014Nov13;57(21):9204-10.
- •PLoSOne.2016Nov11;11(11):e0166415.
- •Shivashankar.2014.9.15.
Description | PreladenantisapotentcompetitiveantagonistofthehumanA2Areceptor(Ki=1.1nM)andhas>1000-foldselectivityoverallotheradenosinereceptors. |
---|---|
IC50&Target | Ki:1.1nM(AdenosineA2Areceptor)[1] |
InVitro | PreladenantalsocompletelyantagonizescAMPincellsexpressingtherecombinanthumanA2Areceptor.PreladenantisdeterminedtohasKBvaluesof1.3nMattheA2Areceptor;thevalueisingoodagreementwiththeKivaluedeterminedintherADIoligandbindingassay.AsimilarfunctionalassaywithA2Breceptor-expressingcellsisusedtodemonstrateselectivityoverA2Breceptors.Inthisassay,theKBvalueforPreladenantis1.2μM,indicatingthatPreladenantis923-foldselectivefortheA2AreceptorovertheA2Breceptor[1]. |
InVivo | Preladenant(1mg/kg)inhibitsL-Dopa-inducedbehavioralsensitizationafterrepeateddailyadministration,whichsuggestsareducedriskofthedevelopmentofdyskinesias.Preladenantexhibitsantidepressant-likeprofilesinmodelsofbehavioraldespair,namelythemousetailsUSPensiontestandthemouseandratforcedswimtest[1].Preladenantproducesadose-dependentreductioninparkinsonianscoresatdosesof1mg/kg(minscore:9.0)and3mg/kg(minscore:6.5).AsubthresholddoseofPreladenantreducesminimumandmeanparkinsonianscoresinanimalstreatedwith3mgkgofL-Dopato5.25and6.88respectively.AWilcoxintestisusedtocompareindividualtreatmentsagainstvehicle.Preladenant(3mg/kg),L-Dopa(3,6,and12mg/kg),andthecombinationofPreladenantandL-Dopa(1or3mg/kg+3mg/kg)areallsignificantlyimprovedontheminimumparkinsonianscore.Inaddition,boththe12mg/kgL-DopaandL-Dopa+Preladenantgroupsaresignificantlyimprovedonbothminimumandmeanparkinsonianscoresrelativetothe3mg/kgL-Dopagroup[2]. |
ClinicalTrial | ViewMoreCollapse |
References |
|
PreparingStockSolutions |
Pleaserefertothesolubilityinformationtoselecttheappropriatesolvent. | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
KinaseAssay [1] | Receptorbindingisperformedusingmembranespreparedfromcellswithrecombinantexpressionofadenosinereceptorsasfollows:humanA2AandHEK293,ratA2AandChinesehamsterovary,humanandratA1andChinesehamsterovary,andhumanA3andHEK293.Radioligandcompetitionbindingassaysareperformedin96-wellplatesinatotalassayvolumeof200μLusingafinaltestdrugconcentrationrangeofbetween0.1and3μM.Membranesaredilutedinassaybuffer,pH7.4(A1andA2A,Dulbecco"sphosphate-bufferedsalinewith10mMMgCl2;A3,50mMTris-HCl,120mMNaCl,10mMMgCl2).Toremoveendogenousadenosinefromthemembranepreparations,4U/mLadenosinedeaminaseisaddedtothemembranes,whicharethenincubatedatroomtemperaturefor15min.Radioligandisaddedtoafinalconcentrationof0.5([3H]SCH58261,A2A),1([3H]DPCPX,A1),or0.25([125I]AB-MECA,A3)nM.Nonspecificbindingisdefinedbyadding100nMCGS15923(A2A),100nMNECA(A1),or100nMDPCPX(A3).Platesareincubatedatroomtemperaturewithagitationfor1.5h(A2AandA1)or2h(A3).MembranesarefilteredontoPackardGF-Bfilterplatesandwashedinice-coldassaybufferusingaBrandelcellharvestertoseparateboundandfreeradioligand.Theplatesaredriedbeforeadditionof45μLofMicroscint20toeachwell.IC50valuesaredeterminingbyfittingthedisplacementcurvesusinganiterativecurve-fittingprogram.KivaluesarecalculatedusingtheCheng-Prusoffequation[1].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. | ||||||||||||||||
CellAssay [1] | PreladenantisdissolvedinDMSOandstored,andthendilutedwithappropriatemediabeforeuse[1]. HEK293cellsstablyexpressingeitherhumanA2AorA2Breceptorsaregrowntoconfluence,harvestedusingenzyme-freecelldissociationbufferandpelletedbycentrifugation(1000g;5min).Thecellsarewashedanddilutedtoafinaldensityof4×106cells/mLinHanks"balancedsaltsolutionsupplementedwith10nMHPS,pH7.4,,5mMMgCl2,and0.2%bovineserumalbumin.Preladenantisdilutedintheabovebufferwithinclusionofthefollowingcomponentstoachievetherespectivefinalassayconcentrations:0.25%DMSO,2U/mLadenosinedeaminase,and100μMRo201724.Cellsuspensions(20μL)arepreincubatedfor15minatroomtemperaturein96-wellplatescontaining25μLofvehicleorPreladenant.CGS-21680(A2A)or5-N-cyclopropylcarboxamidoadenosine(A2B)at10-foldthedesiredconcentrationisthenadded,andthereactionsareincubatedfor15minat37°C.Thereactionsareterminatedbytheadditionof50μLofassay/lysisbuffer.TheconcentrationresponsecurvesforCGS-21680inthepresenceandabsenceofPreladenantareplotted,andtheEC50valuesaredeterminedbyfittingthecurvesusingGraphPadPrismsoftware[1].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. | ||||||||||||||||
AnimalAdministration [1][2] | Preladenantispreparedin50%polyethyleneglycol400(RatandMice)[1]. MiceandRat[1] | ||||||||||||||||
References |
|
MolecularWeight | 503.56 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Formula | C₂₅H₂₉N₉O₃ | ||||||||||||
CASNo. | 377727-87-2 | ||||||||||||
Storage |
| ||||||||||||
Shipping | RoomtemperatureincontinentalUS;mayvaryelsewhere | ||||||||||||
Solvent&Solubility | DMSO *"<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">1> Purity:99.08% 品牌介绍
托烷司琼临床评价药物相关作用适应症托烷司琼CAS号:89565-68-4英文名称:Tropisetron英文同义词:icf205-930;TROPICACID;TROPISETRON;SS-TROPISETRON;BETA-TROPISETRON;Tropisetron(ICS205930);TROPISHTRONHYDROCHLORIDE;Indole-3-carbonylchloride;3-Tropanylindole-3-carboxylate;lαH,5Αh-Tropan-3α-ylindole-3-carboxylate中文名称:托烷司琼中文同义词:托普西隆;托普西龙;曲匹西龙;托烷司琼;Β-托烷司琼;CS-348;Β-内托烷司琼;吲哚-3-甲酰氯;Β-托烷司琼(光学异构体);Β-托烷司琼,托烷司琼异构体CBNumber:CB3236404分子式:C17H20N2O2分子量:284.35MOLFile:89565-68-4.mol化学性质安全信息用途供应商112化学性质安全信息用途供应商112托烷司琼化学性质熔点:201-202°C沸点:448.5±35.0°C(Predicted)密度:1.26储存条件:2-8°C溶解度:H2O:soluble形态:solid酸度系数(pKa):15.38±0.30(Predicted)颜色:whiteCAS数据库:Chemicalbook89565-68-4(CASDataBaseReference)安全信息WGKGermany:3托烷司琼化学药品说明书托烷司琼|药物应用信息托烷司琼性质、用途与生产工艺临床评价Sorbe等报道本品对含顺铂(剂量50~89mg/m2)化疗方案引起的急性呕吐完全控制率为63%。58例恶性肿瘤化疗所致恶心、呕吐者,应用托烷司琼或昂丹司琼8mg分别在同一病人前后2个化疗周期的第1d给药前30min静脉注射,并用地塞米松10mg静脉滴注。结果两药控制急性及迟发性恶心、呕吐的疗效基本相似,均可达81%~100%。本品对强致吐化疗药物顺铂的止吐疗效突出。药物相关作用饮食可略为延长本品的吸收。本品与利福平、苯巴比妥等肝酶诱导药同时使用,可加快代谢,故快代谢型者需增加剂量,慢者则不必。西咪替丁等肝酶抑制药对本品血药浓度无明显影响。适应症托烷司琼临床用于预防和治疗癌症化疗引起的恶心和呕吐。化学性质结晶,熔点201-202℃(二氯甲烷-乙酸乙酯)。单盐酸托烷司琼(TropisetronMonohydroehloride):C17H20N2O2?HCI。[105826-92-4]。熔点283-285℃(分解)。用途有高效性和选择性的5-HT3受体拮抗剂。用于化疗所致的呕吐。用途为5-羟色胺拮抗药生产方法托品醇(I)和酰氯(Ⅱ)反应,可得托烷司琼。托烷司琼上下游产品信息上游原料托品醇下游产品
联络我们
|